IL-10 and TGF-β immunoregulatory cytokines rather than natural regulatory T cells are associated with the resolution phase of Vogt-Koyanagi-Harada (VKH) syndrome

Scandinavian Journal of Immunology

Volumn 72, Issue 1, 2010, Pages 31-37

  Commodaro, A G ^a   Peron, J P S ^b   Genre, J ^b   Arslanian, C ^b   Sanches, L ^a   Muccioli, C ^a   Rizzo, L V ^b,c   Belfort Jr , R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Albert Einstein Research and Education Institute   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOREGULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REMISSION; VOGT KOYANAGI SYNDROME;

ADULT; ANTIGENS, CD4; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; UVEOMENINGOENCEPHALITIC SYNDROME; YOUNG ADULT;

EID: 77953335510     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02401.x     Document Type: Article

References (52)

1. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994 24 : 1434 1440.
2. Persson S, Mikulowska A, Narula S, O'Garra A, Holmdahl R. Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats. Scand J Immunol 1996 44 : 607 614.
3. Rizzo LV, Xu H, Chan C-C, Wiggert B, Caspi RR. IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol 1998 10 : 807 814.
4. Levings MK, Roncarolo MG. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol 2000 106 : S109 12.
5. Letterio JJ. Murine models define the role of TGF-β as a master regulator of immune cell function. Cytokine Growth Factor Rev 2000 11 : 81 7.
6. Kulkarni AB, Huh CG, Becker D et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993 90 : 770 774.
7. Barone KS, Tolarova DD, Ormsby I, Doetschman T, Michael JG. Induction of oral tolerance in TGF-β1 null mice. J Immunol 1998 161 : 154 160.
8. Thorbecke GJ, Umetsu DT, DeKruyff RH, Hansen G, Chen LZ, Hochwald GM. When engineered to produce latent TGF-β1, antigen specific T cells down regulate Th1 cell-mediated autoimmune and Th2 cell-mediated allergic inflammatory processes. Cytokine Growth Factor Rev 2000 11 : 89 96.
9. Gilbert KM, Thoman M, Bauche K, Pham T, Weigle WO. Transforming growth factor-β1 induces antigen-specific unresponsiveness in naïve T cells. Immunol Invest 1997 26 : 459 472.
10. Kitani A, Chua K, Nakamura K, Strober W. Activated self-MHC reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. J Immunol 2000 165 : 691 702.
11. Prud'homme GJ, Piccirillo CA. The inhibitory effects of transforming growth factor-β1 (TGF-β1) in autoimmune diseases. J Autoimmun 2000 14 : 23 42.
12. Caspi RR, Kuwabara T, Nussenblatt RB. Characterization of a suppressor cell line which downgrades experimental autoimmune uveoretinitis in the rat. J Immunol 1988 140 : 2579 2584.
13. + regulatory T cells that protect from IRBP-induced retinal autoimmunity. J Exp Med 2006 203 : 851 856.
14. + regulatory T cells suppresses experimental autoimmune uveoretinitis. Br J Ophthalmol 2007 91 : 105 110.
15. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000 101 : 455 458.
16. + suppressor T cells. Immunol Rev 2001 182 : 58 67.
17. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995 155 : 1151 1164.
18. Sakaguchi S, Toda M, Asano M, Itoh M, Morse SS, Sakaguchi N. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J Autoimmun 1996 9 : 211 220. (Pubitemid 26163865)
19. Belfort R Jr., Nishi M, Hayashi S, Abreu MT, Petrilli AM, Plut RC. Vogt-Koyanagi-Harada's disease in Brazil. Jpn J Ophthalmol 1988 32 : 344 347.
20. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995 39 : 265 292.
21. Rao NA. Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye 1997 11 : 213 216.
22. Read RW, Rao NA, Cunningham ET. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol 2000 11 : 437 442.
23. Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. Semin Ophthalmol 2005 20 : 183 190.
24. + T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci 2006 47 : 2547 2554.
25. Norose K, Yano A, Wang XC et al. Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1994 35 : 33 9.
26. Imai Y, Sugita M, Nakamura S, Toriyama S, Ohno S. Cytokine production and helper T cell subsets in Vogt-Koyanagi-Harada's disease. Curr Eye Res 2001 22 : 312 318.
27. Li B, Yang P, Zhou H et al. Upregulation of T-bet expression in peripheral blood mononuclear cells during Vogt-Koyanagi-Harada disease. Br J Ophthalmol 2005 89 : 1410 1412.
28. + T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 2007 119 : 1218 1224.
29. Liu L, Yang P, He H et al. Leptin increases in Vogt-Koyanagi-Harada (VKH) disease and promotes cell proliferation and inflammatory cytokine secretion. Br J Ophthalmol 2008 92 : 557 561.
30. Read RW, Holland GN, Rao NA et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 2001 131 : 647 652.
31. + CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci 2008 49 : 3475 3482.
32. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev 2001 182 : 68 79.
33. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006 212 : 28 50.
34. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007 8 : 277 284.
35. Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest 2007 37 : 987 996.
36. Bonelli M, Savitskaya A, von Dalwigk K et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 2008 20 : 861 868.
37. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J. Quantitative and qualitative normal regulatory T cells re not capable of inducing suppression in SLE patients due to Tcell resistance. Lupus 2008 17 : 289 294.
38. + regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006 83 : 1432 1446.
39. + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005 105 : 735 741.
40. Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004 200 : 277 285.
41. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003 21 : 273 276. (Pubitemid 37410115)
42. Franz B, Fritzsching B, Riehl A et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007 56 : 1910 1920.
43. Yates J, Whittington A, Mitchell P, Lechler RI, Lightstone L, Lombardi G. Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis. Clin Exp Immunol 2008 153 : 44 55.
44. + regulatory T-cells in type 1 diabetes. Diabetes 2007 56 : 604 612.
45. + T-regulatory cells in noninfectious uveitis. Arch Ophthalmol 2009 127 : 407 413.
46. + regulatory T cells in patients with Behçet's disease. Clin Exp Rheumatol 2006 24 : S71 8.
47. + regulatory T cells. J Immunol 2004 172 : 5986 5993.
48. + regulatory T cells from human peripheral blood. J Immunol 2001 166 : 7282 7289.
49. + CD25- precursors. J Immunol 2002 169 : 4183 4189.
50. Damico FM, Cunha-Neto E, Goldberg AC et al. T-Cell Recognition and Cytokine Profile Induced by Melanocyte Epitopes in Patients with HLA-DRB1*0405- Positive and -Negative Vogt-Koyanagi-Harada Uveitis. Invest Ophthalmol Vis Sci 2005 46 : 2465 2471.
51. Lacomba MS, Martin CM, Chamond RR, Galera JM, Omar M, Estevez EC. Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch Ophthalmol 2000 118 : 768 772.
52. de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 1995 27 : 537 541.